Vyome Therapeutics is an innovation-driven, clinical stage speciality pharmaceutical company, which has novel platform technologies and a robust pipeline of novel drugs for antibiotic-resistant acne and other opportunistic skin pathogens.
Vyome Therapeutics management team members are the leaders in the field, with deep expertise, demonstrated capability and a proven track record of successfully launching over 50 products in dermatology & other life sciences areas, and building visionary companies.
Vyome has a robust pipeline of IP based products targeting multiple indications. The company's lead molecule (VB 1953), which targets the substantial unmet need in the drug resistant C. acne prescription market, completed a proof of concept clinical study at the end of 2017 with desirable results and a phase 2 trial of VB 1953 has been initiated in the US. Earlier in February 2017, Vyome announced Phase 1 Clinical Trial Results after USFDA accepted Vyome's Investigational New Drug Application.
Vyome Therapeutics will:
Continuously strive to innovate, research and develop novel platform technologies and a robust pipeline of novel drugs for the treatment of antibiotic resistant acne and other opportunistic skin pathogens, consequently grow into a global clinical and commercial stage speciality pharmaceutical company with robust organization, systems and IP portfolio.
Vyome will achieve its vision by living by its core values of:
Uncompromising Integrity entails upholding the highest standards of professional commitment, business ethics and corporate governance.
Business Innovation involves looking at novel product development and commercialization strategies, and being open to new ways of collaborating.
Scientific Excellence entails championing creative thinking in science that can lead to development of novel platforms at a significantly lowered cost.
Seamlessness means breaking down physical and mental silos to generate higher value through effective ideation and speedier execution.
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.